Market Place
Sourcing Support
Junshi Biosciences’ Toripalimab Gains Approval In India, Hong Kong
16 Oct 2024 //
BIOSPECTRUM
Junshi Biosciences Toripalimab Approved For Marketing In India
15 Oct 2024 //
GLOBENEWSWIRE
Junshi Announces EC Approval for Marketing of Toripalimab
24 Sep 2024 //
GLOBENEWSWIRE
Junshi Biosciences Announces 2024 Interim Financial Results
30 Aug 2024 //
GLOBENEWSWIRE
Junshi`s Toripalimab sNDA Accepted For First-Line Melanoma Treatment
12 Aug 2024 //
GLOBENEWSWIRE
EMA CHMP Issues Positive Opinion On Junshi Biosciences` Toripalimab
26 Jul 2024 //
GLOBENEWSWIRE
Junshi`s Toripalimab Combo NDA Accepted For Liver Cancer
17 Jul 2024 //
GLOBENEWSWIRE
Junshi Biosciences Receives sNDA Approval for Toripalimab in Advanced TNBC
25 Jun 2024 //
GLOBENEWSWIRE
Junshi Announces sNDA Approval For Toripalimab in 1st-Line Lung Cancer
18 Jun 2024 //
GLOBENEWSWIRE
Junshi, Coherus move Loqtorzi closer to another approval
13 Jun 2024 //
FIERCE PHARMA
Junshi Biosciences Announces Ph3 Study of Toripalimab Combined with Bevacizumab
11 Jun 2024 //
GLOBENEWSWIRE
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
24 Apr 2024 //
GLOBENEWSWIRE
Junshi Bio Announces Approval of the sNDA for Toripalimab for Renal Cancer
07 Apr 2024 //
GLOBENEWSWIRE
Junshi Biosciences Announces Toripalimab™s NDA Accepted
01 Feb 2024 //
GLOBENEWSWIRE
Junshi Announces JAMA Publication from Phase 3 of Perioperative Toripalimab
17 Jan 2024 //
GLOBENEWSWIRE
Coherus exits TIGIT deal with Junshi, three months after Surface Oncology buyout
10 Jan 2024 //
ENDPTS
Junshi Announces Publication of Results from Phase 3 Trial of Toripalimab
09 Jan 2024 //
GLOBENEWSWIRE
Junshi Announces Approval of Supplemental New Drug Application for Toripalimab
02 Jan 2024 //
GLOBENEWSWIRE
Junshi Announces Chemical Entity Application for Toripalimab Accepted by TGA
01 Dec 2023 //
GLOBENEWSWIRE
Junshi Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023
27 Oct 2023 //
GLOBENEWSWIRE
Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab
19 Jul 2023 //
GLOBENEWSWIRE
Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab
11 Jul 2023 //
GLOBENEWSWIRE
FDA inspection of China-based site making Coherus` drug ends with 3 observations
31 May 2023 //
ENDPTS
Junshi Announces Acceptance of sNDA for Toripalimab with Chemotherapy
23 May 2023 //
GLOBENEWSWIRE
Junshi Biosciences Announces Collaboration with Dr. Reddy™Toripalimab
07 May 2023 //
GLOBENEWSWIRE
Junshi Bio touts lung cancer data as it looks to expand PD-1 label in China
22 Apr 2023 //
ENDPTS
Junshi`s Lynparza rival hits mark in ovarian cancer phase 3
13 Apr 2023 //
FIERCE BIOTECH
Junshi Bio Announces Acceptance of the Supplemental NDA for Toripalimab
11 Apr 2023 //
GLOBENEWSWIRE
Junshi Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer
11 Apr 2023 //
GLOBENEWSWIRE
Junshi Biosciences Announces 2022 Full Year Financial Results
31 Mar 2023 //
GLOBENEWSWIRE
Junshi Bios, Rxilient Biotech Partner Develop Toripalimab in Southeast Asia
30 Mar 2023 //
CONTRACT PHARMA
Junshi Bios Announces Establishment of Joint Venture with Rxilient Biotech
28 Mar 2023 //
GLOBENEWSWIRE
Junshi`s lipid lowering drug hits phase 3 goals
01 Mar 2023 //
FIERCE BIOTECH
Junshi & Coherus Announce Positive Final Overall Survival Results of JUPITER-02
15 Feb 2023 //
GLOBENEWSWIRE
Junshi Biosciences Announces Approval for Marketing of VV116 in China
30 Jan 2023 //
GLOBENEWSWIRE
China approves two domestically developed COVID drugs
29 Jan 2023 //
REUTERS
Junshi says toripalimab succeeded in Phase III perioperative NSCLC study
19 Jan 2023 //
GLOBENEWSWIRE
Junshi Biosciences Announces NEJM Publication of Results of Ph3 Study of VV116
29 Dec 2022 //
GLOBENEWSWIRE
Hikma & Junshi Biosciences sign exclusive licensing agreementfor cancer treatment drug toripalimab
27 Dec 2022 //
PRESS RELEASE
Junshi Announces data from Phase I study of anti-BTLA antibody Tifcemalimab
10 Dec 2022 //
GLOBENEWSWIRE
Junshi Announces Submission of a MAA for Toripalimab to UK the Medicines
24 Nov 2022 //
GLOBENEWSWIRE
Junshi Announces Approval of Supplemental Application for Adalimumab
21 Nov 2022 //
GLOBENEWSWIRE
Junshi Announces Submission of a Marketing Authorization EMAfor Toripalimab
14 Nov 2022 //
GLOBENEWSWIRE
Junshi Biosciences & Coherus Announce Publication of +ve Results from CHOICE-01
12 Oct 2022 //
GLOBENEWSWIRE
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination
20 Sep 2022 //
GLOBENEWSWIRE
Junshi Biosciences Announces 2022 Interim Financial Results
30 Aug 2022 //
GLOBENEWSWIRE
Junshi Announces FDA Approval of Investigational New Drug Application for JS110
25 Aug 2022 //
GLOBENEWSWIRE
Junshi Announces Acceptance of Supplemental Application for Adalimumab Injection
17 Aug 2022 //
GLOBENEWSWIRE
Junshi Biosciences Receives Orphan Designation from the EC for Toripalimab
21 Jul 2022 //
GLOBENEWSWIRE
Two months after CRL, FDA accepts Coherus, Junshi`s resubmission of Toripalimab
07 Jul 2022 //
ENDPTS
Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology at ASCO
06 Jun 2022 //
GLOBENEWSWIRE
I-Mab, Junshi`s cancer combo worked best as first-line treatment
28 May 2022 //
FIERCEBIOTECH
Junshi reports positive Phase III data in mild-to-moderate Covid-19
24 May 2022 //
CLINICALTRIALSARENA
Junshi Nabs NMPA Approval of sNDA for Toripalimab plus Paclitaxel and Cisplatin
16 May 2022 //
GLOBENEWSWIRE
FDA rejects two China-developed cancer drugs
03 May 2022 //
BIOPHARMADIVE
Junshi Bio, Coherus Present Results of PIII Study of Toripalimab at AACR
08 Apr 2022 //
GLOBENEWSWIRE
Junshi Bio Nabs FDA Approval of IND for Anti-CD112R MAb in Advanced Solid Tumors
04 Apr 2022 //
GLOBENEWSWIRE
Junshi Biosciences Announces Full Year 2021 Financial Results
31 Mar 2022 //
GLOBENEWSWIRE
Junshi Bio Begins Dosing in China in P III Trial of VV116 in COVID-19
16 Mar 2022 //
GLOBENEWSWIRE
